July 15, 2026

KRAS G12D–Mutated Metastatic Pancreatic Cancer: Zoldonrasib Plus Chemotherapy

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown high rates of activity when combined with standard first-line chemotherapy, ...

The ASCO Post

June 22, 2026

A Burning Question: Can Wildfire Smoke Drive Cancer Risk?

Exposure to wildfire smoke was associated with significantly elevated risks of several cancers, including lung, colorectal, breast, bladder, and blood cancers, according to evidence from the Prostate,...

The ASCO Post

June 18, 2026

Advancing Clinical Trials and Decision-Making With Synthetic Real-World Data

Synthetic real-world data generated by AI can model treatment patterns and clinical outcomes across large patient cohorts while accelerating clinical trials and drug development, according to Eddy Saa...

The ASCO Post

June 10, 2026

2026 ASCO Breakthrough Meeting to Highlight New Advances in Liquid Biopsy, Metabolic Risks, and Tailored Therapies for Asian Populations

The ASCO Breakthrough meeting being held in Singapore this month will bring together global oncology professionals in Asia to discuss the latest cancer research advances across multiple disease sites ...

The ASCO Post

May 29, 2026

Behind the Scenes of the 2026 ASCO Annual Meeting

In an interview with The ASCO Post, Jo Chien, MD, Professor of Medicine at University of California, San Francisco, and Chair of the 2026 ASCO Annual Meeting Scientific Program Committee, peels back t...

The ASCO Post

March 24, 2026

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

The ASCO Post

February 24, 2026

Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer

“Encorafenib/cetuximab plus FOLFIRI is an additional standard of care for patients needing FOLFIRI in the first-line setting,” reported study authors at the 2026 ASCO Gastrointestinal Cancers Symposiu...

The ASCO Post

February 19, 2026

Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO

Studies at the meeting spanned established uses of radiopharmaceutical therapies and early signals for new indications, while also addressing what clinics need in place to safely offer these treatment...

The ASCO Post

February 11, 2026

Highlights From the 2025 ASH Annual Meeting & Exposition

At this year’s American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, we had the opportunity to navigate both manned and unmanned traffic, contend with temperamental weather,...

The ASCO Post

November 12, 2025

JADPRO Live 2025: United in Care

Jadpro